Business Context and Reporting Period
This Form 8-K, dated January 25, 2023, reports the consummation of a business combination between Health Sciences Acquisitions Corporation 2 (HSAC2) and Orchestra BioMed, Inc. On January 25, 2023, HSAC2 was domesticated from the Cayman Islands to Delaware and renamed Orchestra BioMed Holdings, Inc. ("New Orchestra"). The merger closed on January 26, 2023, resulting in Orchestra becoming a wholly-owned subsidiary of New Orchestra. The company ceased to be a shell company upon closing, and its common stock began trading on the Nasdaq Stock Market under the symbol "OBIO" on January 27, 2023.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, or cash flow figures for the combined entity within this text; such data is incorporated by reference from the Proxy Statement/Prospectus. However, the following capital structure and transaction metrics are disclosed:
- Shares Issued: 20,191,338 shares of New Orchestra Common Stock were issued to Orchestra stockholders at an exchange ratio of 0.465 shares of New Orchestra stock for each Orchestra share.
- Reserved Shares: 5,523,834 shares were reserved for issuance pursuant to converted Orchestra stock options and warrants.
- Total Outstanding: Immediately following the closing, 31,614,079 shares of New Orchestra Common Stock were outstanding.
- Warrants: 3,075,936 New Orchestra Warrants were outstanding.
- Forward Purchases: RTW Investments funds purchased $10 million of shares; Medtronic purchased approximately $10 million ($9.9 million prior to domestication and $0.1 million post-domestication).
- Backstop Agreement: RTW Funds purchased 1,808,512 shares at $10.00 per share to ensure a minimum available cash condition of $60 million.
Material Changes and Transaction Details
The primary material change is the transformation of HSAC2 from a Cayman Islands exempted company into a Delaware corporation and the acquisition of Orchestra BioMed. Key transaction mechanics include:
- Domestication: HSAC2 Ordinary Shares converted one-for-one into New Orchestra Common Stock.
- Earnout Structure: Approximately 91% of Orchestra stockholders elected to participate in an earnout. Up to 8,000,000 additional shares are contingent on stock price milestones: 4,000,000 shares if the volume-weighted average price (VWAP) reaches $15.00, and an additional 4,000,000 shares if the VWAP reaches $20.00, over specified periods within five years of closing.
- Sponsor Forfeiture: The Sponsor forfeited 25% (1,000,000 shares) of its New Orchestra Common Stock, subject to release upon achieving the $15.00 and $20.00 milestones. Additionally, the Sponsor forfeited 50% of its private warrants (750,000 warrants), which were reissued to Orchestra employees and directors.
- Lock-Up Periods: Insider shares and RTW Funds shares are subject to a 12-month lock-up. Other holders are subject to a 6-month lock-up, extended to 12 months for Earnout Participants.
Guidance, Outlook, Risks, and Management Commentary
The filing contains extensive forward-looking statements regarding the company's ability to raise financing, achieve profitability, and commercialize product candidates. No specific financial guidance or revenue projections are provided in this text.
- Risks: Key risks include the ability to secure future financing, regulatory approval of product candidates, reliance on third-party manufacturers, competition, and the potential for the earnout milestones not to be met.
- Management Changes: New employment agreements were executed for CEO David P. Hochman ($595,000 base salary) and President/COO Darren R. Sherman ($495,000 base salary). Both are eligible for discretionary bonuses (target 80% of base) and future equity grants to reach specific ownership percentages (4.6% for Hochman, 4.3% for Sherman).
- Accounting Change: The company dismissed WithumSmith+Brown, PC, and appointed Ernst & Young LLP as its independent registered public accounting firm effective upon closing.
- Dividends: The Board does not anticipate declaring cash dividends in the foreseeable future, intending to retain earnings for operations.
Investor Verification Checklist
- Verify the pro forma financial information and historical financial statements of Orchestra BioMed referenced in the Proxy Statement/Prospectus (Exhibit 99.5 and pages F-18, F-66).
- Confirm the specific terms of the earnout milestones ($15.00 and $20.00 VWAP thresholds) and the timeline for the five-year earnout period.
- Review the lock-up expiration dates for major shareholders (RTW Funds, Medtronic, and the Sponsor) to assess potential near-term selling pressure.
- Examine the details of the Forward Purchase and Backstop Agreements to understand the capital raised and the conditions under which the $60 million cash floor was maintained.
- Assess the impact of the new employment agreements and equity incentive plans on future dilution and executive retention.